

CPI-203

Bromodomain-containing protein 4 (BRD4) inhibitor; JQ1 analog

Catalog #100-1644

5 mg

Product Description

CPI-203 is a JQ1 analog and an inhibitor of bromodomain-containing protein 4 (BRD4; IC_{50} = 26 nM). BRD4 is a protein in the bromodomain and extra-terminal (BET) family involved in transcriptional regulation. CPI-203 inhibits BRD4-mediated phosphorylation of serine 2 on the C-terminal domain of RNA polymerase II (Devaiah et al.), impacting the expression of key oncogenes and anti-apoptotic proteins (Filippakopoulos & Knapp).

Alternative Names: CPI-267203

CAS Number: 1446144-04-2


Chemical Formula: $C_{19}H_{18}ClN_5OS$

Molecular Weight: 399.9 g/mol

Purity: $\geq 98\%$

Chemical Name: (S)-2-(4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl) acetamide

Structure:



Properties

Product Format:	A white to off-white powder
Stability and Storage:	Product stable at -20°C as supplied. As a precaution, STEMCELL recommends storing all small molecules away from direct light. For long-term storage, store with a desiccant. Stable as supplied for 12 months from date of receipt.
Preparation:	<ul style="list-style-type: none">• DMSO \leq 60 mM For example, to prepare a 10 mM stock solution in DMSO, resuspend 1 mg in 250 μ L of DMSO. Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported; however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application. Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

DIFFERENTIATION

- Represses Myc expression, resulting in hematopoietic stem and progenitor cells (HSPCs) maintenance in a mouse model (Knudsen et al.).
- Promotes expansion of human umbilical cord blood HSPCs and increases proportion of megakaryocyte differentiation (Hua et al.).

CANCER RESEARCH

- Enhances the effect of immunotherapy in a mouse model of liver cancer by inhibiting programmed death receptor 1 expression (Niu et al.).

References

- Devaiah BN et al. (2012) BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. *Proc Natl Acad Sci U S A* 109(18): 6927–32.
- Filippakopoulos P & Knapp S. (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat Rev Drug Discov* 13(5): 337–56.
- Hua P et al. (2020) The BET inhibitor CPI203 promotes ex vivo expansion of cord blood long-term repopulating HSCs and megakaryocytes. *Blood* 136(21): 2410–15.
- Knudsen KJ et al. (2015) ERG promotes the maintenance of hematopoietic stem cells by restricting their differentiation. *Genes Dev* 29: 1915–29.
- Niu X et al. (2022) CPI-203 improves the efficacy of anti-PD-1 therapy by inhibiting the induced PD-L1 overexpression in liver cancer. *Cancer Sci* 113(1): 28–40.

Related Products

For a complete list of small molecules available from STEMCELL Technologies, visit www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2024 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design, and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.